DR. JAMES W LYNCH JR. MD
Prescription History 1770524704
Internal Medicine - Medical Oncology in Gainesville, FL
Quality Rating: 78.18 out of 100 score
NPI Status: Active since June 09, 2006
Contact Information
1600 SW ARCHER RD
GAINESVILLE, FL
ZIP 32610
Phone: (352) 392-3000
Fax: (352) 392-8530
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JAMES W LYNCH JR. MD, an active Medical Oncology specialist practicing in Gainesville, FL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 84 documented patient claims. Among these therapy options, the most frequently utilized medication is Venclexta, which accounts for 29 claims alone.
Brukinsa
Generic Formulation: ZanubrutinibSpecialty: Medical OncologyProvider Avg Cost Per Claim
$10,118.57
State Avg Cost Per Claim
$13,901.93
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.
Calquence
Generic Formulation: Acalabrutinib MaleateSpecialty: Medical OncologyProvider Avg Cost Per Claim
$14,884.52
State Avg Cost Per Claim
$13,788.69
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.
Imbruvica
Generic Formulation: IbrutinibSpecialty: Medical OncologyProvider Avg Cost Per Claim
$16,086.07
State Avg Cost Per Claim
$14,870.86
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).
Venclexta
Generic Formulation: VenetoclaxSpecialty: Medical OncologyProvider Avg Cost Per Claim
$6,522.28
State Avg Cost Per Claim
$8,886.48
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JAMES W LYNCH JR. MD provides transparency into local medical care patterns within Gainesville, FL.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
